目的：探讨程序性死亡受体-配体1（PD-L1）在晚期非小细胞肺癌中的表达及其预后价值。方法：收集70例非小细胞肺癌患者肿瘤组织，通过免疫组化检测肿瘤组织中PD-L1的表达。Kaplan-Meier生存曲线及多变量Cox回归模型分析PD-L1表达与患者预后的关系。结果：70例肺癌标本中有36例（51.4%）PD-L1高表达。肿瘤细胞PD-L1高表达的患者预后较差，无进展生存时间较短[14个月（95% CI：12.06~17.45）vs 20个月（95% CI：17.05~23.26），P=0.007]。结论：PD-L1在国内非小细胞肺癌中也呈高表达，同时其表达水平与非小细胞肺癌患者的预后密切相关，可能是非小细胞肺癌的独立预后指标。

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
[2] 周婉婉,梁冰,王效静,等.非小细胞肺癌患者外周血h TERT mRNA水平检测的临床意义[J].东南大学学报(医学版),2017,36(2):217-221.
[3] TANVETYANON T,CREELAN B C,CHIAPPORI A A.Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer[J].Cancer Control,2014,21(1):32-39.
[4] RUIZ R,HUNIS B,RAEZ L E.Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines[J].Curr Oncol Rep,2014,16(9):1-10.
[5] MARRONE K A,BRAHMER J R.Immune checkpoint therapy in non-small cell lung cancer[J].Cancer J,2016,22(2):81-91.
[6] RIBAS A.Tumor immunotherapy directed at PD-1[J].New Eng J Med,2012,366(26):2517-2519.
[7] RIZVI N A,MAZIÈRES J,PLANCHARDD,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
[8] GETTINGER S N,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody,BMS-936558,ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J].J Clin Oncol 2015,33(18):2004-2012.
[9] RECK M,POPAT S,REINMUTH N,et al.Metastatic non-small-cell lung cancer (NSCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2014,25(Suppl 3):iii27-39.
[10] OHAEGBULAM K C,ASSAL A,LAZAR-MOLNAR E,et al.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].TrendsMolec Med,2015,21(1):24-33.
[11] 李晓雷,徐俊,胡欣,等.多中心多学科治疗模式下对局部晚期非小细胞肺癌患者的新辅助化疗疗效及对预后影响的临床研究[J].东南大学学报(医学版),2018,37(4):667-672.
[12] CHEN S,WANG R X,LIU Y,et al.PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy[J].Int J Cancer,2017,140(6):1384-1395.
[13] CALDERARO J,ROUSSEAU B,AMADDEO G,et al.Programmed death ligand 1 expression in hepatocellular carcinoma:relationship with clinical and pathological features[J].Hepatol,2016,64(6):2038-2046.
[14] WEBB J R,MILNE K,NELSON B H.PD-1 and CD103 are widely coexpressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer[J].Cancer Immunol Res,2015,3(8):926-935.
[15] ETO S,YOSHIKAWA K,NISHI M,et al.Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection[J].Gastric Cancer,2016,19(2):466-471.
[16] KIM M Y,KOH J,KIM S,et al.Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma:comparison with tumor-infiltrating T cells and the status of oncogenic drivers[J].Lung Cancer,2015,88(1):24-33.